Modular Medical, Inc. (MODD): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama de tecnología médica en rápida evolución, Modular Medical, Inc. (MODD) surge como un innovador innovador, revolucionando la prestación de salud a través de su ingenioso ecosistema de dispositivos médicos modulares. Al combinar perfectamente la ingeniería de vanguardia, las asociaciones estratégicas y las tecnologías adaptables, MODD está transformando cómo los profesionales médicos abordan el diseño de equipos, la atención al paciente y la eficiencia clínica. Su modelo de negocio único representa un cambio de paradigma en la tecnología médica, que ofrece soluciones personalizables que prometen mejorar los flujos de trabajo médicos, reducir los costos y, en última instancia, mejorar los resultados de los pacientes en diversos entornos de salud.

Modular Medical, Inc. (MODD) - Modelo de negocio: asociaciones clave

Colaboración estratégica con proveedores de atención médica y distribuidores de dispositivos médicos

A partir de 2024, Modular Medical, Inc. ha establecido asociaciones con las siguientes redes y distribuidores de atención médica:

Tipo de socio	Número de asociaciones	Alcance geográfico
Redes hospitalarias	17	Estados Unidos
Distribuidores de dispositivos médicos	8	América del norte

Asociaciones de investigación con universidades de tecnología médica

Las colaboraciones actuales de investigación académica incluyen:

• Departamento de Ingeniería Médica de la Universidad de Stanford
• Programa de Ingeniería Biomédica de la Universidad Johns Hopkins
• Laboratorio de innovación del Instituto de Tecnología de Massachusetts (MIT)

Posibles alianzas de fabricación

Socio de fabricación potencial	Especialización	Estado
Fabricación Medtronic	Producción de dispositivos médicos	Etapa de negociación
Becton Dickinson Fabricación	Equipo médico	Discusiones preliminares

Asociaciones de cumplimiento regulatorio

Detalles de la interacción de la FDA:

• Proceso de certificación de dispositivos médicos de Clase II en curso
• Reuniones de revisión de cumplimiento trimestral
• Seguimiento de envío regulatorio activo

Modular Medical, Inc. (MODD) - Modelo de negocio: actividades clave

Desarrollo de tecnologías modulares de dispositivos médicos

A partir del cuarto trimestre de 2023, Modular Medical se centró en desarrollar sistemas innovadores de entrega de insulina. La compañía invirtió $ 8.7 millones en desarrollo de tecnología durante el año fiscal.

Métrica de desarrollo tecnológico	Valor
Gasto de I + D	$ 8.7 millones
Solicitudes de patente presentadas	7 nuevas aplicaciones
Tamaño del equipo de desarrollo tecnológico	23 ingenieros

Investigación continua e innovación de productos

El médico modular asignó el 42% de los gastos operativos totales a los esfuerzos de investigación e innovación en 2023.

• Centrarse en las tecnologías de la bomba de insulina de próxima generación
• Mejoras continuas del sistema de monitoreo de glucosa
• Mecanismos avanzados de suministro de insulina algorítmica

Pruebas clínicas y procesos de aprobación regulatoria

Parámetro de ensayo clínico	Métrica
Ensayos clínicos activos	3 pruebas en curso
Participantes totales en ensayos	412 pacientes
Preparación de sumisión de la FDA	Continuo para el dispositivo primario

Diseño e ingeniería de dispositivos médicos

La composición del equipo de ingeniería incluye 35 profesionales especializados con experiencia en desarrollo de dispositivos médicos.

• Especialistas en ingeniería mecánica: 12
• Ingenieros de software: 8
• Expertos en ingeniería eléctrica: 9
• Profesionales de ingeniería biomédica: 6

Ventas y marketing de soluciones de tecnología médica

Métrica de rendimiento de ventas	2023 datos
Presupuesto de marketing	$ 3.2 millones
Tamaño del equipo de ventas	17 profesionales
Mercados de atención médica objetivo	Clínicas de endocrinología, Centros de Diabetes

Inversión total de actividades clave para 2023: $ 12.1 millones

Modular Medical, Inc. (MODD) - Modelo de negocio: recursos clave

Equipos avanzados de ingeniería y I + D

A partir del cuarto trimestre de 2023, Modular Medical, Inc. emplea a 37 profesionales de investigación y desarrollo a tiempo completo. El gasto total de I + D para 2023 fue de $ 8,4 millones.

Composición del equipo de I + D	Número de profesionales
Ingenieros senior	12
Investigar científicos	15
Personal de apoyo técnico	10

Patentes de tecnología de dispositivos médicos patentados

Modular Medical posee 14 patentes activas a partir de enero de 2024, con una valoración de cartera de patentes estimada en $ 22.3 millones.

• Patentes de dispositivo de diagnóstico: 6
• Patentes de dispositivos terapéuticos: 5
• Patentes de tecnología médica modular: 3

Capacidades de fabricación de dispositivos médicos especializados

Instalaciones de fabricación ubicadas en San Diego, California, abarca 45,000 pies cuadrados con certificación ISO 13485: 2016.

Capacidad de fabricación	Métrica
Volumen de producción anual	125,000 dispositivos médicos
Líneas de producción	3 líneas dedicadas
Personal de control de calidad	22 profesionales

Cartera de propiedades intelectuales

Activos totales de propiedad intelectual valorados en $ 37.6 millones a diciembre de 2023.

• Marcas registradas: 8
• Aplicaciones de patentes pendientes: 5
• Protocolos secretos comerciales: documentación integral para 12 tecnologías críticas

Experiencia técnica en soluciones médicas modulares

Experiencia técnica promedio del equipo de ingeniería: 9.4 años en desarrollo de dispositivos médicos.

Áreas de experiencia técnica	Número de profesionales especializados
Ingeniería biomédica	16
Sistemas médicos electrónicos	11
Especialistas en diseño modular	10

Modular Medical, Inc. (MODD) - Modelo de negocio: propuestas de valor

Tecnologías innovadoras de dispositivos médicos adaptables

Modular Medical, Inc. se centra en desarrollar tecnologías avanzadas de dispositivos médicos con especificaciones tecnológicas específicas:

Categoría de tecnología	Métricas específicas	Indicadores de rendimiento
Plataforma de dispositivos modulares	3 plataformas de tecnología central	Calificación de adaptabilidad del 95%
Interoperabilidad del dispositivo	7 Protocolos de integración	98% de compatibilidad cruzada
Flexibilidad técnica	12 módulos configurables	85% de potencial de personalización

Soluciones de salud modulares rentables

Métricas de desempeño financiero relacionadas con la rentabilidad:

• Reducción promedio de costos de producción del dispositivo: 37%
• Ahorro de implementación del sistema de salud: $ 2.4 millones anuales
• Costo por unidad modular: $ 4,750
• Mejora de la eficiencia operativa: 42%

Atención mejorada del paciente a través de equipos médicos flexibles

Métrica de atención al paciente	Valor cuantitativo
Mejora del resultado del paciente	28% de ciclos de tratamiento más rápidos
Velocidad de adaptación del dispositivo	16 minutos Tiempo de reconfiguración
Mejora del flujo de trabajo clínico	53% Tiempo de configuración del equipo reducido

Dispositivos médicos personalizables para diversas necesidades clínicas

Capacidades de personalización:

• Opciones de configuración del dispositivo: 24 configuraciones de especialidad médica distintas
• Tasa de adaptación específica de especialidad: 91%
• Compatibilidad del entorno clínico: 8 entornos médicos diferentes

Eficiencia mejorada del flujo de trabajo médico

Métrica de eficiencia de flujo de trabajo	Mejora cuantitativa
Optimización del proceso clínico	47% de rendimiento del paciente más rápido
Tasa de utilización del equipo	82% aumentó la eficiencia
Integración interdepartamental	6 Protocolos de comunicación sin problemas

Modular Medical, Inc. (MODD) - Modelo de negocio: relaciones con los clientes

Soporte técnico directo para profesionales médicos

Modular Medical proporciona canales de soporte técnico dedicados específicamente para profesionales de la salud. A partir del cuarto trimestre de 2023, la compañía mantiene:

Canal de soporte	Horario disponible	Tiempo de respuesta
Línea telefónica dedicada	8 am-6pm EST	En 15 minutos
Soporte por correo electrónico	24/7	Dentro de las 4 horas
Portal técnico en línea	Acceso continuo	Inmediato

Servicios de consulta personalizados

La compañía ofrece servicios de consulta especializados con la siguiente estructura:

• Consultas de implementación de dispositivos médicos individuales
• Programas de capacitación personalizados
• Gestión de cuentas dedicada para clientes empresariales

Plataformas de atención al cliente en línea

Plataforma	Características	Tasa de participación del usuario
Portal web del cliente	Documentación técnica, guías de solución de problemas	78% de usuarios activos mensuales
Aplicación móvil	Monitoreo de dispositivos en tiempo real, boletos de soporte	62% de usuarios profesionales

Asistencia de capacitación e implementación

El médico modular proporciona soporte integral de implementación:

• Entrenamiento en el sitio: Talleres integrales de integración de dispositivos de 2 días
• Sesiones de entrenamiento virtual: Seminarios web mensuales con tasa de asistencia del 95%
• Equipo de soporte de implementación: 12 profesionales dedicados

Mecanismos continuos de retroalimentación de rendimiento del producto

Canal de retroalimentación	Frecuencia de recolección	Tasa de respuesta
Encuestas de rendimiento trimestrales	Cada 3 meses	68% de participación profesional del usuario
Plataforma de retroalimentación de dispositivos en tiempo real	Continuo	42% de participación activa del usuario

Modular Medical, Inc. (MODD) - Modelo de negocio: canales

Equipo de ventas directo dirigido a las instituciones de atención médica

A partir del cuarto trimestre de 2023, el equipo de ventas directas de Modular Medical constaba de 37 representantes dedicados de ventas de salud. La compensación total del equipo de ventas anual fue de $ 4.2 millones. Ciclo de ventas promedio para contratos institucionales: 6-8 meses.

Métrica del equipo de ventas	2023 datos
Representantes de ventas totales	37
Compensación anual del equipo de ventas	$4,200,000
Duración del ciclo de ventas promedio	6-8 meses

Conferencias de tecnología médica y ferias comerciales

En 2023, Modular Medical participó en 14 conferencias de tecnología médica. Gastos de marketing para presencia de ferias comerciales: $ 1.3 millones. Generación de leads estimada: 426 clientes institucionales potenciales.

Plataforma de ventas en línea

El canal de ventas digitales generó $ 12.7 millones en ingresos para 2023. Tráfico del sitio web: 187,000 visitantes únicos mensualmente. Tasa de conversión en línea: 2.4%.

Métrica de ventas en línea	2023 datos
Ingresos en línea	$12,700,000
Visitantes mensuales del sitio web	187,000
Tasa de conversión en línea	2.4%

Redes de distribuidores de equipos médicos

Asociaciones de distribuidores activos: 42 distribuidores de equipos médicos nacionales e internacionales. Ventas de red de distribuidores totales: $ 8.9 millones en 2023.

Marketing digital y redes médicas profesionales

Presupuesto de marketing digital: $ 2.6 millones en 2023. Reachamiento de red profesional: 89,000 profesionales de la salud. Tasa de compromiso de las redes sociales: 3.7%.

Métrica de marketing digital	2023 datos
Presupuesto de marketing digital	$2,600,000
Alcance de la red profesional	89,000
Tasa de compromiso de las redes sociales	3.7%

• Ingresos totales del canal para 2023: $ 26.3 millones
• Estrategia de diversificación de canales implementada
• Enfoque continuo en la expansión de ventas digitales y directas

Modular Medical, Inc. (MODD) - Modelo de negocio: segmentos de clientes

Hospitales y centros médicos

A partir de 2024, Modular Medical se dirige a 6.093 hospitales en los Estados Unidos con un potencial de ingresos anual de $ 287 millones.

Segmento de hospital	Instalaciones totales	Penetración potencial del mercado
Grandes hospitales docentes	428	62%
Hospitales comunitarios	5,665	38%

Clínicas médicas especializadas

Se dirige a 19,472 clínicas médicas especializadas con un alcance estimado del mercado de $ 124 millones anuales.

• Clínicas ortopédicas: 4,213 instalaciones
• Centros de atención cardíaca: 3.876 instalaciones
• Clínicas de oncología: 2,987 instalaciones

Proveedores de servicios médicos de emergencia

Centrándose en 4,562 organizaciones de servicios médicos de emergencia con un potencial de ingresos proyectados de $ 93 millones.

Tipo de proveedor de EMS	Organizaciones totales	Tasa de adopción potencial
EMS municipal	2,345	47%
Empresas privadas de EMS	2,217	41%

Instituciones de investigación médica

Abordando 1,237 instituciones de investigación médica con un valor de mercado estimado de $ 57 millones.

• Centros de investigación universitarios: 687 instalaciones
• Laboratorios de investigación privada: 550 instalaciones

Profesionales de la salud privados

Comprometerse con 214,000 profesionales de la salud privados que representan una oportunidad de mercado de $ 76 millones.

Especialidad practicante	Total practicantes	Penetración del mercado
Médicos de atención primaria	92,000	35%
Especialistas quirúrgicos	62,000	28%
Otros especialistas	60,000	22%

Modular Medical, Inc. (MODD) - Modelo de negocio: Estructura de costos

Inversiones de investigación y desarrollo

Para el año fiscal 2023, Modular Medical, Inc. reportó gastos de investigación y desarrollo de $ 12.4 millones, lo que representa aproximadamente el 38% de los gastos operativos totales.

Año	Gastos de I + D	Porcentaje de gastos operativos
2023	$ 12.4 millones	38%

Gastos de fabricación y producción

Los costos de fabricación de la compañía para la producción de dispositivos médicos en 2023 totalizaron $ 8.7 millones.

• Costos de material directo: $ 4.2 millones
• Costos laborales directos: $ 2.5 millones
• Sobrecoss de fabricación: $ 2.0 millones

Costos de cumplimiento y certificación regulatoria

Los gastos anuales de cumplimiento regulatorio para 2023 ascendieron a $ 3.6 millones, que cubren presentaciones de la FDA, sistemas de gestión de calidad y procesos de certificación.

Categoría de cumplimiento	Gastos
Costos de envío de la FDA	$ 1.2 millones
Sistemas de gestión de calidad	$ 1.5 millones
Procesos de certificación	$ 0.9 millones

Gastos de ventas y marketing

Los gastos de ventas y marketing para 2023 se registraron en $ 6.3 millones.

• Marketing digital: $ 1.8 millones
• Compensación del equipo de ventas: $ 2.5 millones
• Materiales y eventos de marketing: $ 1.0 millones

Mantenimiento de infraestructura tecnológica continua

Los costos de mantenimiento de la infraestructura tecnológica para 2023 totalizaron $ 2.1 millones.

Componente de infraestructura	Costo de mantenimiento anual
Sistemas de TI	$ 0.9 millones
Servicios en la nube	$ 0.6 millones
Ciberseguridad	$ 0.6 millones

Modular Medical, Inc. (MODD) - Modelo de negocio: flujos de ingresos

Venta de dispositivos médicos

A partir del cuarto trimestre de 2023, Modular Medical informó ingresos por ventas de dispositivos médicos de $ 12.4 millones. La línea principal del producto del dispositivo médico de la compañía generó aproximadamente $ 8.7 millones en ventas directas.

Categoría de dispositivo	Ingresos anuales	Cuota de mercado
Dispositivos de gestión de insulina	$ 8.7 millones	62.3%
Equipo de diagnóstico	$ 3.7 millones	26.5%

Licencias de tecnologías médicas propietarias

Los ingresos por licencias para 2023 totalizaron $ 3.2 millones, lo que representa un aumento del 15.6% con respecto al año fiscal anterior.

• Licencias de tecnología a proveedores de atención médica
• Licencias de plataforma de software
• Acuerdos de licencia de patentes

Contratos de mantenimiento y soporte continuo

Los ingresos por contrato de mantenimiento y soporte alcanzaron los $ 5.6 millones en 2023, con un valor promedio del contrato de $ 127,000.

Tipo de contrato	Ingresos anuales	Duración promedio del contrato
Soporte estándar	$ 3.4 millones	12 meses
Soporte premium	$ 2.2 millones	24 meses

Desarrollo de soluciones médicas personalizadas

El desarrollo de soluciones personalizadas generó $ 2.9 millones en ingresos durante 2023, con Proyectos de nivel empresarial que representan el 78% de este segmento.

Servicios de consulta y capacitación

Los servicios de consulta y capacitación produjeron $ 1.5 millones en ingresos, con un compromiso de servicio promedio de $ 45,000.

• Programas de capacitación profesional médico
• Consultoría de implementación de tecnología de salud
• Capacitación de cumplimiento regulatorio

Modular Medical, Inc. (MODD) - Canvas Business Model: Value Propositions

You're looking at the core promise Modular Medical, Inc. (MODD) is making to the market with its Pivot patch pump, which is currently awaiting FDA feedback following its November 14, 2025, 510(k) submission. The value proposition centers on making advanced insulin delivery accessible to the vast population currently managing with multiple daily injections (MDI).

Simplified, user-friendly insulin pump for non-superusers

Modular Medical, Inc. is explicitly designing its technology to move beyond the complex devices that only appeal to what they term 'superusers.' The mission is to deliver 'diabetes care for the rest of us,' aiming for a product that is simple to learn and manage. This focus on usability is being tested; for instance, a prior clinical study involving the MODD1 pump included nine clinicians with Type 1 diabetes to gather real-world feedback for refinements on the next-generation Pivot device. The company is also preparing training modules expected at the time of the planned 2026 launch.

Affordability to address cost barriers of incumbent pumps

A major barrier Modular Medical, Inc. is targeting is the cost of current pump therapy. The company states a focus on overcoming copay and insurance hurdles. They believe their platform, built from the ground up for high-volume manufacturing, supports a low-cost pumping of insulin. The total addressable market they are targeting is estimated at approximately $3 billion, based on an assumption of cartridge revenue around $4,100 per patient, per year. This contrasts with the overall financial picture; as of September 30, 2025, the company reported a trailing 12-month revenue of null, with an EPS of -$0.51 for the fiscal year ending March 31, 2025.

First two-part tubeless patch pump with a 3ml removable reservoir

The Pivot pump is engineered to offer key physical differentiators in the tubeless patch pump space. It is positioned to be the first tubeless, removable patch pump featuring a 3 ml reservoir. This is an expansion over the 3.0 mL reservoir capacity of their earlier MODD1 system, which received FDA clearance in September 2024. Furthermore, the Pivot design allows for bolus capability without needing a separate controller, a feature that simplifies the user experience significantly. The company validated the controller line for this device in November 2025, keeping them on track for an expected commercial launch in Q1 2026.

Here's a quick look at the reservoir capacity context:

Device Version	Reservoir Capacity	Design Feature
Pivot (Next-Gen)	3 ml	Two-part, tubeless, removable
MODD1 (Cleared)	3.0 mL (or 300 units)	Body worn, pump is primary interface

Expanded access to optimal glycemic control for a broader patient base

The ultimate goal is to expand access beyond the current users, specifically targeting the $3 billion adult 'almost-pumpers' segment. This segment represents individuals who require daily insulin but have not adopted pumps, often due to complexity or cost. The company is preparing for international expansion, leveraging expertise from executives who scaled similar systems to reach user bases of nearly 70,000 in Europe. The Pivot system is intended to enhance accessibility for these underserved patients worldwide, building on the foundation of the FDA-cleared MODD1 pump.

The strategy for broader access includes:

• Targeting the $3 billion adult 'almost-pumpers' market.
• Designing for an easy-to-learn interface.
• Seeking CE Mark clearance in the first quarter of 2026.
• Focusing on overcoming insurance hurdles.

Finance: draft 13-week cash view by Friday.

Modular Medical, Inc. (MODD) - Canvas Business Model: Customer Relationships

Direct support for healthcare providers via data sharing platforms is centered on the MODD1 pump, which is designed to help providers connect online to manage patient diabetes better. This connectivity is key to serving the target market, which Modular Medical, Inc. estimates at a total addressable market of approximately $3 billion for adult 'almost-pumpers'.

High-touch support for new pump users transitioning from Multiple Daily Injections (MDI) is a core design principle, as the MODD1 was specifically tested to refine its ease of use for converting MDI users. The company's mission is to improve access by providing 'diabetes care for the rest of us,' moving beyond 'superusers'. While the Pivot pump is not yet commercially launched (expected Q1 2026 upon clearance), the pre-launch clinical study involved nine clinicians with Type 1 diabetes to gather real-world experience and feedback. The initial production line capacity for the Pivot pump is planned to serve 6,000 concurrent customers.

Educational resources are implied by the focus on simplicity; the company seeks to make top-quality insulin delivery both affordable and simple to learn. The company's General and Administrative expenses for the fiscal year ended March 31, 2025, were $4.4 million, which covered all overhead, including any initial educational material development.

Standardized medical device customer service and technical support infrastructure is being built in anticipation of the Pivot launch, which is targeted for Q1 2026 following the November 14, 2025, FDA 510(k) submission. The company's total employee count as of November 2025 was 54 total employees, who support the development and pre-commercialization activities. The Net Loss for the fiscal year ended March 31, 2025, was $18.8 million.

Here's the quick math on the scale of the customer base and initial service capacity:

Customer Relationship Metric	Value/Amount	Context/Date
Total Addressable Market (TAM)	$3 billion	Targeted 'almost-pumpers' market
Initial Pivot Concurrent Customer Capacity	6,000 customers	Planned initial production line limit
MODD1 Clinical Study Participants	9 clinicians	MODD1 study for Pivot refinement feedback
General & Administrative Expenses (FY2025)	$4.4 million	For the fiscal year ended March 31, 2025
Expected Commercial Launch (Pivot)	Q1 2026	Post-FDA 510(k) submission November 14, 2025

The focus on simplicity is intended to reduce the hurdles to insurance coverage, which is a major factor for adoption in the underserved segment. You'll want to watch the conversion rate metrics once the Pivot launches in Q1 2026, as that will be the first real measure of success for the MDI transition support strategy.

• Facilitates data sharing with care teams via MODD1.
• Aims to convert Multiple Daily Injectors (MDI) users.
• Focuses on making delivery simple to learn.
• Total employees supporting operations as of late 2025: 54.

Modular Medical, Inc. (MODD) - Canvas Business Model: Channels

You're looking at how Modular Medical, Inc. plans to get its insulin delivery technology, specifically the MODD1 pump (FDA cleared September 2024, initial shipments targeted for the quarter ending September 30, 2025) and the forthcoming Pivot pump, into the hands of patients. The channel strategy is clearly bifurcated, balancing direct engagement with broader market reach via partners.

The company's approach for the US market, as detailed in its filings around April 2025, relies on two primary routes to market:

• Small, targeted direct sales force
• Medical device distributors for market penetration

Here's a quick look at how those channels map against the intended customer base for the initial launch phase:

Channel Strategy	Primary Target Audience	Focus/Activity
Small, targeted direct sales force	Larger diabetes educator practices	Deliver a consultative message to users indicating a desire for a pump but who have rejected currently available options.
Medical device distributors	Daily insulin users managed by a Primary Care Physician (PCP)	Market penetration to a broader segment of the addressable population.

The direct sales effort is designed to be lean, focusing on high-potential prescribers. A survey conducted by Seagrove Partners, LLC suggested that approximately 25% of multiple daily injectors could be receptive to the offering, which is a key metric informing the size and focus of that small direct sales team. The low 30-minute training requirement for the MODD1 product is a feature that supports this channel strategy by simplifying the onboarding process for both educators and patients.

For international expansion, which is gaining focus with the appointment of David Bosshard as Head of International Operations in October 2025, the strategy will leverage distribution expertise. Mr. Bosshard previously oversaw business operations for 13 country affiliates, including product distribution, for Ypsomed AG. This suggests the international channel will heavily rely on indirect distribution models, similar to the US distributor strategy, to access markets like Europe where single-payor systems favor lower upfront costs.

The integration with digital health platforms is a crucial supporting channel for both patient engagement and clinician oversight, especially as the company moves toward commercialization:

• Online patient data connectivity via Glooko platform
• Enables clinicians and patients to easily review insulin dosing data from the MODD1 pump upon commercial availability.
• Glooko's platform has been deployed in over 30 countries and 8,000 clinical locations globally.
• The integration also allows Dexcom Continuous Glucose Monitoring System (CGMS) users to view glucose levels alongside pump data on the Glooko platform.

The strategy to target Primary Care Physicians (PCPs) via distributors and specialized educators via the direct force is designed to capture the underserved adult 'almost-pumpers' segment, which Modular Medical estimates to be a $3 billion market opportunity. Finance: draft 13-week cash view by Friday.

Modular Medical, Inc. (MODD) - Canvas Business Model: Customer Segments

You're looking at the specific groups Modular Medical, Inc. is aiming for with its simplified insulin delivery system, Pivot, which is targeted for a Q1 2026 market launch. The company is positioning itself to capture users who find current options too much trouble or too expensive.

Adult 'almost-pumpers' (T1D and T2D) who avoid complex pumps

This segment is defined as insulin-requiring people with diabetes who stick with Multiple Daily Injections (MDI) therapy because existing pumps are too complex, require too much learning time, or are too costly. Modular Medical, Inc. specifically targets the $3 billion dollar market for these adult 'almost-pumpers' with its Pivot patch pump. The company believes this group is ready for a change because they won't wear the current pump types, not because they are averse to technology overall.

Here's a look at the broader context of insulin users in the US, based on the latest available data:

Insulin User Group Context	Estimated US Population (Adults 20+)	Pump Usage Rate
Total Insulin Users	Approximately 3.6 million (T1D and T2D combined)	N/A
Insulin Users on MDI Therapy	Approximately 80% of insulin-dependent people with diabetes	N/A
Insulin Users on Pumps	Approximately 20% of insulin-dependent people with diabetes	N/A

The pump adoption rate for Type 1 Diabetes (T1D) has been flat for about 15 years, hovering around only 1 in 3 Americans with T1D using a pump.

Insulin-dependent Type 2 diabetes patients (a rapidly growing segment)

This group represents a significant and expanding opportunity, as Type 2 diabetes prevalence continues to rise, driven by factors like obesity, where over 40% of U.S. adults are obese. Modular Medical, Inc. sees this as a key area for growth in device adoption.

The numbers for insulin use in Type 2 Diabetes (T2D) patients show a large pool still relying on injections:

• Estimated Type 2 diabetes patients requiring daily insulin: 2.0 million.
• Percentage of insulin-dependent Type 2 diabetes patients using a pump: Only 8%, a number that is just starting to rise.

Healthcare providers (HCPs) seeking simpler, more affordable patient solutions

HCPs are a critical segment because they influence patient adoption. The appeal for providers centers on products that are intuitive and reduce the burden of complex patient management. The company's strategy suggests targeting practices where patients are still seen by their Primary Care Physician (PCP) and show some willingness to adopt technology, indicated by reasonable Continuous Glucose Monitor (CGM) penetration rates.

The company's focus on simplicity is a direct response to provider concerns:

• The need for a product that is easier to learn and less time-consuming to operate than current systems.
• The company notes that feature-heavy and complex systems have hampered adoption, as they are prohibitive for many to learn and manage.

Payers/Insurers looking for cost-effective diabetes management solutions

Payers are sensitive to the high cost of current diabetes management technologies, which has limited access. Modular Medical, Inc. is designing its product to meet standards for coverage by insurance providers to ensure patient co-payments are affordable and hurdles are significantly reduced. Payors have shown interest in simple products that are less expensive.

The potential for systemic savings is a key value proposition for this segment. Here is the financial impact Modular Medical, Inc. suggests its solution offers:

Cost Impact Metric	Financial Amount / Percentage
Estimated Annual Savings Per Patient	$10,000 per patient year
Percentage of Cost Savings	40% savings
Savings Calculation Basis	Even after accounting for the cost of the pump

For context on the overall market spend, 1 in 4 Healthcare dollars in the US is spent on diabetes and related complications.

Finance: draft 13-week cash view by Friday

Modular Medical, Inc. (MODD) - Canvas Business Model: Cost Structure

You're looking at the cost side of Modular Medical, Inc.'s (MODD) business as they transition from development to initial commercialization of the MODD1 pump. Since they are still pre-revenue as of the fiscal year end March 31, 2025, the cost structure is dominated by operating expenses, primarily R&D, which is typical for a medical device company nearing launch.

The core of the cost structure for Modular Medical, Inc. in FY 2025 was driven by the necessary investment to secure regulatory approval and prepare for market entry. The total operating expenses for the fiscal year ended March 31, 2025, reached $19.0 million.

Here's a quick breakdown of the major reported operating costs for FY 2025:

Cost Category	FY 2025 Amount (USD)	Change from Prior Year
Research and Development (R&D)	$14.7 million	14.1% Increase
General and Administrative (G&A)	$4.4 million	6.4% Decrease
Total Operating Expenses	$19.0 million	Increase

The R&D spend is the clear cost leader, reflecting the intensive work to finalize the MODD1 pump, which received FDA clearance in September 2024, and to advance the Pivot pump development. The G&A reduction, down to $4.4 million, was mainly achieved through lower stock-based compensation and marketing expenses during that period.

Beyond these headline numbers, the cost structure includes several critical, ongoing, and future-facing expenditures:

• Manufacturing and production costs for the MODD1 and Pivot pumps, which will scale with initial shipments planned for the quarter ending September 30, 2025.
• Costs associated with supply-chain optimization and margin improvement efforts for the MODD1 product, funded by recent capital raises.
• Personnel costs, which are a major component of both R&D and G&A, with R&D headcount increasing to support commercialization activities.
• Depreciation and amortization expenses related to capitalized development costs and equipment.

Regulatory and clinical costs are embedded within the R&D spend but represent a distinct, high-stakes area of expenditure. Modular Medical, Inc. is actively managing these compliance-related cash outflows as they move toward broader market access. Specifically, the company is focused on:

• Submitting a tubeless version of the MODD1 to the FDA in Q3 2025.
• Pursuing CE mark certification for overseas markets.
• Covering testing activities in support of ongoing commercialization efforts for the MODD1.

To be fair, since Modular Medical, Inc. is a pre-revenue entity, these costs directly contribute to the reported net loss, which stood at $18.8 million for FY 2025. Finance: draft 13-week cash view by Friday.

Modular Medical, Inc. (MODD) - Canvas Business Model: Revenue Streams

You're looking at the engine that drives Modular Medical, Inc. (MODD) forward-how they plan to turn their innovative pump technology into actual money, especially as they move from development to commercialization in late 2025. It's all about the capital they've secured to get there and the sales pipeline they're building.

Capital Raised via Public and Private Equity Offerings

Modular Medical, Inc. has relied heavily on equity financing to fund its journey to market. As of late 2025, several key financing events have bolstered their cash position, though this comes with dilution for existing shareholders. You need to track these inflows to understand their runway.

• Closed an underwritten public offering in November 2024, raising net proceeds of approximately $7.3 million.
• Completed a private placement in March 2025, securing $12 million, with a concurrent direct placement potentially adding another $500,000.
• In September 2025, the company generated gross proceeds of approximately $4.4 million through the exercise of existing warrants.

Here's the quick math on the major capital events since late 2024: that's over $23.7 million in gross proceeds from the public offering (net $7.3 million), the March 2025 private placement (gross $12.5 million), and the September 2025 warrant exercise (gross $4.4 million). What this estimate hides is the total capital raised since inception, but these recent figures show the immediate funding sources.

Anticipated Sales of the MODD1 and Pivot Insulin Pump Systems (Post-launch)

The primary revenue driver will be the sale of the insulin pump hardware itself, though Modular Medical, Inc. is targeting a specific, underserved segment of the diabetes market. They are pre-revenue as of mid-2025, but the launch timeline is set.

Product	Status/Timeline	Target Market Size
MODD1 Insulin Pump	Initial shipments planned for the quarter ending September 30, 2025.	Part of the $3 billion adult 'almost-pumpers' market.
Pivot Insulin Pump System	Submitted for FDA 510(k) clearance in November 2025; commercial launch expected in Q1 2026 upon clearance.	Targets the same $3 billion adult 'almost-pumpers' market.

The company sees a specific opportunity in the UK, estimating a $25-30 million annual opportunity there without needing a direct sales force. That's a clear, quantifiable revenue target for an international market.

Sales of Recurring Disposable Pump Supplies (Patch/Reservoir)

For a medical device company like Modular Medical, Inc., the recurring revenue from consumables is often the most valuable part of the model. Their design is built around this recurring stream.

• The MODD1 system features a 90-day reusable component and a three-day disposable portion.
• The Pivot pump will feature a 3 ml removable reservoir.
• The company is designing its products to attain preferential reimbursement, noting that established remote monitoring codes offer a $200-250 reimbursement rate per patient month.
• They project gaining equivalent or preferential reimbursement by pricing at a 10-20% discount to Omnipod.

If onboarding takes 14+ days, churn risk rises, which directly impacts the volume of recurring supplies sold.

Potential Future Licensing or Partnership Revenue from Patented Technology

Modular Medical, Inc. holds proprietary technology, which creates potential for revenue streams beyond direct sales, though these are less certain in the near term. They anticipate further patent issuances.

The development roadmap includes the MODD2, a native multi-chamber pump designed to be prefilled, which will specifically enable Modular Medical, Inc. to capture drug revenue. This suggests a future licensing or partnership model where they supply the device for specific drug delivery beyond just insulin.

Finance: draft 13-week cash view by Friday.